Alnylam Pharma (ALNY) Tops Q1 EPS by 37c
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $266.11 --0%
EPS Growth %: -39.0%
Financial Fact:
Net loss per common share - basic and diluted: -1.05
Today's EPS Names:
CAN, UNFI, SUNB, More
EPS Growth %: -39.0%
Financial Fact:
Net loss per common share - basic and diluted: -1.05
Today's EPS Names:
CAN, UNFI, SUNB, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of ($1.52), $0.37 better than the analyst estimate of ($1.89). Revenue for the quarter came in at $99.5 million versus the consensus estimate of $91.56 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Evercore ISI on Jersey Mike's Subs (JMKE): 'Anticipating a positive outlook'
- Barclays Downgrades Ipsen SA (IPN:FP) (IPSEF) to Underweight
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
